The combination of accelerating revenue growth, margin expansion, and a clear path to sustained profitability makes this a strong fundamental inflection. Traders should monitor whether the market prices in the raised guidance and if volume trends remain strong in Q1 2026.
Price Chart
Executive Summary
BillionToOne reported strong Q4 and full-year 2025 results with revenue doubling year-over-year, driven by significant growth in both prenatal and oncology testing volumes and pricing. The company achieved profitability for the first time at both the operating and net income levels and raised its 2026 revenue guidance to $430M–$445M while projecting positive operating income for the full year.
Key Financial Metrics
Key Facts
- Q4 2025 revenue was $96.1 million, up 113% YoY; full-year 2025 revenue was $305.1 million, up 100% YoY
- Gross margin expanded to 71% in Q4 2025 from 57% in Q4 2024, and 68% for full-year 2025 from 53% in 2024
- Achieved $10.3 million operating income in Q4 2025 vs. $11.7 million loss in prior year; $16.0 million operating income for full-year 2025 vs. $47.1 million loss in 2024
- Net income was $4.4 million ($0.11 diluted EPS) in Q4 2025 vs. $11.5 million net loss ($1.13 loss per share) in Q4 2024
- Raised 2026 revenue guidance to $430M–$445M (41%–46% growth) and expects positive GAAP operating income for the year
Financial Impact
Revenue doubled in 2025 to $305.1M with 100% YoY growth, gross margin up 15 pts to 68%, and company turned profitable with $16.0M operating income. 2026 revenue guidance implies another $125M+ in growth.
Risk Factors
- Forward-looking guidance is subject to execution risk, particularly in payer coverage expansion and test adoption
- Increased operating expenses (up 50% YoY) could pressure margins if revenue growth slows
- Stock may be sensitive to any future dilution given recent IPO and high share count increase
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3249729 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 30, 2026 26d ago | Insider Cluster | $105.76 | awaiting T+60 | — | $111.46 (−5.39%) |
Sep 28, 2026 28d ago | Insider Cluster | $118.18 | awaiting T+60 | — | $111.46 (+5.68%) |
Sep 23, 2026 4w ago | Insider Cluster | $124.90 | awaiting T+60 | — | $111.46 (+10.76%) |
Sep 22, 2026 4w ago | Institutional Cluster | $116.07 | awaiting T+60 | — | $111.46 (−3.97%) |
Sep 21, 2026 5w ago | Insider Cluster | $116.07 | awaiting T+60 | — | $111.46 (+3.97%) |
Sep 16, 2026 5w ago | Insider Cluster | $110.67 | awaiting T+60 | — | $111.46 (−0.72%) |
Sep 11, 2026 6w ago | Insider Cluster | $100.82 | awaiting T+60 | — | $111.46 (+10.56%) |
Sep 11, 2026 6w ago | Insider Cluster | $100.82 | awaiting T+60 | — | $111.46 (+10.56%) |
Aug 27, 2026 8w ago | Insider Cluster | $93.24 | awaiting T+60 | — | $111.46 (+19.55%) |
Aug 27, 2026 8w ago | Insider Cluster | $93.24 | awaiting T+60 | — | $111.46 (+19.55%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers